GLP-1-Medikamente zur Gewichtsreduktion wurden in einer großen Kohortenstudie mit einer geringeren Brustkrebsinzidenz in Verbindung gebracht. Eine Studie mit mehr als 110.000 Frauen ergab, dass die Wahrscheinlichkeit, an Brustkrebs zu erkranken, bei Frauen, die GLP-1-Medikamente einnahmen, um etwa 30 % geringer war als bei Frauen, die keine GLP-1-Medikamente einnahmen.
https://www.pennmedicine.org/news/glp-1-use-linked-to-lower-breast-cancer-incidence
15 Kommentare
GLP-1 use linked to lower breast cancer incidence in large cohort study
The Penn Medicine study sets the stage for a multi-site clinical trial to determine whether GLP-1 drugs are associated with a lower risk of developing breast cancer.
A retrospective analysis of more than 110,000 women between the ages of 45 and 80 found that those who took GLP-1 medications were about 30 percent less likely to develop breast cancer than those who did not take GLP-1 medications, according to research.
https://ascopubs.org/doi/10.1200/OP-26-00485
Could this simply be that the weight loss reduces the amount of cells than could become cancerous?
Edit: As has been pointed out, weight loss will not significantly reduce the amount of fat cells you have – it will just deflate them.
Didnt people *just* start taking these items?
How can this be tracked at such high numbers?
Is there any control of variables at all here? Otherwise it may be very obvious that those with money and care about their health to take medicines to slim down may also have other better health outcomes.
So if we eliminate that correlation is not the same as causation… Is it fair to assume that being at a healthy weight is better at having a lower cancer risk than being overweight?
Yeah okay just tell me when it’s affordable already instead of bragging about what benefits the rich get.
How does it compare to the differences in occurrence between obese vs healthy weight population?
As per the study, it’s likely due to the fat loss caused by the GLP-1 medication. I didn’t know that there are around 13 types of obesity-related cancers. So interesting.
I would have loved to see a more in-depth discussion section focusing on metabolic pathways etc. Here’s what I could find from the study:
> At the genomic level, higher expression of GLP-1 agonists is associated with increased survival
in breast and other cancers 29, providing a possible biological basis for cancer-prevention.
Similarly, impaired GIP receptor signaling is linked to increased breast cancer risk, with each copy
of the GIPR variant rs1800437 (E354Q) conferring additional risk.30 There is limited evidence
that GLP-1 agonists can improve survival among women with breast cancer
> A recent study of
older adults (≥66 years) with breast cancer and type 2 diabetes found improved survival for patients
using GLP-1 agonists compared to those on dipeptidyl peptidase-4 inhibitors.31 Since weight gain
alone in women with BMI ≥25 after a breast cancer diagnosis is associated with increased all-
cause mortality, 32 it remains unclear whether the survival benefits of GLP-1 agonists extend
beyond their effects on weight. In fact, the questions of whether GLP-1 agonists directly impact
tumor growth, whether they reshape the tumor microenvironment, and whether they reduce
systemic inflammation independent of the impact on weight are major knowledge gaps.
There has been speculation about whether GLP-1 agonists could serve as a “magic bullet” for..
Fat makes estrogen. Estrogen drives many forms of breast cancer. Fat is inflammatory. Chronic inflammation drives cancer. This is a very simple explanation and I am sure there are many more hypotheses but it makes plenty of sense. (am doctor, dis not read the article).
Or the drug company sponsored the study.
Obesity increases breast cancer risk, so no suprise that effective weight loss drugs will decrease cancer risk.
GLP-1 drugs also lower afib risk. No surprise either, obesity is a risk factor for afib.
What can’t these drugs do by now?
„While our study was observational and does not definitively confirm an association between GLP-1 medications and reduced breast cancer incidence, it does add to the growing body of evidence suggesting that it’s worth investigating these weight-loss drugs as potential cancer prevention tools,” McDonald said.
Miracle drug keeps getting better.
I wonder if the study is factoring socioeconomic consideratons too. I might be wrong, but wouldn’t it make sense that that higher income demographics that can afford to be on thesee drugs also have access to better screening for cancer and overall more access to healthcare? Cancer strikes rich or old but I’m sure the economic landscape has to be a factor in somewhere.